Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Molecular Cancer Research : MCR
|
March 17, 2018
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation
Tie Li, Christopher D Cox, Byram H Ozer, et al.
Neuro-Oncology Practice
|
June 9, 2025
Implications of sociodemographic and clinical factors on symptom burden: Age-specific survivorship care in the primary central nervous system tumor population
Kimberly R Robins, Tricia Kunst, Jennifer Reyes, et al.
Frontiers in Oncology
|
March 20, 2026
Case Report: Molecular diagnostics and clinical courses of two adult spinal pilocytic astrocytoma long-term survivors with GTF2I::BRAF fusion
Lorenzo Argao, Pinar E Zerk, Hsiang-Chih Lu, et al.
AJNR. American Journal of Neuroradiology
|
May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)
Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Neuro-Oncology
|
May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells
Morgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Neuro-Oncology Advances
|
April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Shuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Acta Neuropathologica
|
May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors
Andrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Neuro-Oncology Advances
|
April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial
Byram H Ozer, Adam L Cohen, Howard Colman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial
Byram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Journal of Neuro-Oncology
|
March 1, 2024
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
James L Rogers, Thomas Wall, Alvina A Acquaye-Mallory, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Molecular Cancer Research : MCR
|
March 17, 2018
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation
Tie Li, Christopher D Cox, Byram H Ozer, et al.
Neuro-Oncology Practice
|
June 9, 2025
Implications of sociodemographic and clinical factors on symptom burden: Age-specific survivorship care in the primary central nervous system tumor population
Kimberly R Robins, Tricia Kunst, Jennifer Reyes, et al.
Frontiers in Oncology
|
March 20, 2026
Case Report: Molecular diagnostics and clinical courses of two adult spinal pilocytic astrocytoma long-term survivors with GTF2I::BRAF fusion
Lorenzo Argao, Pinar E Zerk, Hsiang-Chih Lu, et al.
AJNR. American Journal of Neuroradiology
|
May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)
Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Neuro-Oncology
|
May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells
Morgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Neuro-Oncology Advances
|
April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Shuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Acta Neuropathologica
|
May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors
Andrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Neuro-Oncology Advances
|
April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial
Byram H Ozer, Adam L Cohen, Howard Colman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial
Byram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Journal of Neuro-Oncology
|
March 1, 2024
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
James L Rogers, Thomas Wall, Alvina A Acquaye-Mallory, et al.
Page
of 3